SCHEMBL441814

SCHEMBL441814

NC(CS)C(=O)N(CC(=O)O)C(=O)C(N)CCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPEP Q07075 7/20 0.50
ANPEP P15144 4/20 0.50
GRM8 O00222 1/20 0.48
GRM6 O15303 1/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GSR P00390 1/20 0.48
CYP1A2 P05177 1/20 0.48
GRIK1 P39086 1/20 0.48
GRM5 P41594 1/20 0.48
GRIA1 P42261 1/20 0.48
GRIA2 P42262 1/20 0.48
GRIA3 P42263 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48
GRIA4 P48058 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIK2 Q13002 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27719619 1.00 ENPEP (0.50) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL3358170 0.84 DPP4 (0.51) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL3909782 0.84 GRM8 (0.50) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL27584091 0.83 GRM8 (0.47) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL30050502 0.82 DPP4 (0.50) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL18285489 0.82 DPP4 (0.50) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL28606931 0.82 DPP4 (0.50) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL25246132 0.79 DPP4 (0.47) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL18339143 0.79 DPP4 (0.47) ENPEPANPEPGRM8GRM6GRIN2D
SCHEMBL10795389 0.79 GSR (0.52) GRM8GRM6GRIN2DGRIN3BGSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118897023-B Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay 中国农业科学院北京畜牧兽医研究所 2025-03-25 CN claimed
US-6239111-B1 DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2001-05-29 US claimed
EP-4097145-B1 REDUCTION OF ADSORPTION LEUKOCARE AG (DE) 2026-01-28 EP disclosed
US-20250262258-A1 MICROORGANISM WITH HIGH TRIPEPTIDE PRODUCTIVITY AND USE THEREOF SAMYANG CORPORATION (KR) 2025-08-21 US disclosed
US-20250255843-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC 2025-08-14 US disclosed
EP-4568653-A1 COMPOSITIONS TO INCREASE GLUTATHIONE LEVELS AND PROCESSES FOR MAKING THE SAME The ProImmune Company, LLC (US) 2025-06-18 EP disclosed
EP-4561372-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF Nature's Fusions, LLC (US) 2025-06-04 EP disclosed
CN-117243971-B Prefabricated nano enzyme and preparation method and application thereof 郑州大学 2025-05-16 CN disclosed
CN-118897023-B Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay 中国农业科学院北京畜牧兽医研究所 2025-03-25 CN disclosed
CN-118897023-A Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay 中国农业科学院北京畜牧兽医研究所 2024-11-05 CN disclosed
CN-118829414-A Composition for improving wrinkles comprising retinol enhancers as an active ingredient 株式会社LG生活健康 2024-10-22 CN disclosed
EP-0869809-A1 CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF Balazovsky, Mark Borisovich (RU) 1998-10-14 EP disclosed
EP-0848951-A1 Use of acetylcysteine for the manufacture of a medicament for the treatment of chronic ulcers Johnson & Johnson Medical Ltd. (GB) 1998-06-24 EP disclosed
WO-1997021444-A9 CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF 1997-10-30 WO disclosed
WO-1997021444-A1 CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF BALAZOVSKY MARK BORISOVICH (RU) 1997-06-19 WO disclosed
EP-0706655-A1 MCA ASSAY/KIT FOR DETECTING METAL CATIONS BIONEBRASKA, INC. (US) 1996-04-17 EP disclosed
EP-0690709-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CERTAIN VIRUSES AND AUTOIMMUNE DISEASES AND THE PROCEDURE OF ITS PREPARATION DINU, Constantin Romulus (RO) 1996-01-10 EP disclosed
WO-1995000845-A1 MCA ASSAY/KIT FOR DETECTING METAL CATIONS BIONEBRASKA, INC. (US) 1995-01-05 WO disclosed
WO-1994022438-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CERTAIN VIRUSES AND AUTOIMMUNE DISEASES AND THE PROCEDURE OF ITS PREPARATION DINU CONSTANTIN ROMULUS (RO) 1994-10-13 WO disclosed
US-4689347-A CALCIUM SODIUM ETHYLENEDIAMINETETRAACETATE, CALCIUM GLUCONATE AND CYSTEINE CENTRALA INDUSTRIALA DE MEDICAMENTE COSMETICE COLORANTI SI LACURI (RO) 1987-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250255843-A1 COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF AHCY, MGMT, CBS ENPEP 93/4885ANPEP 109/4885GRM8 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.